SummaryThe broadly neutralizing antibody 2G12 recognizes a conserved cluster of high-mannose glycans on the surface envelope spike of HIV, suggesting that the “glycan shield” defense of the virus can be breached and may, under the right circumstances, serve as a vaccine target. In an attempt to recreate features of the glycan shield semisynthetically, oligomannosides were coupled to surface lysines on the icosahedral capsids of bacteriophage Qβ and cowpea mosaic virus (CPMV). The Qβ glycoconjugates, but not CPMV, presented oligomannose clusters that bind the antibody 2G12 with high affinity. However, antibodies against these 2G12 epitopes were not detected in immunized rabbits. Rather, alternative oligomannose epitopes on the conjugates wer...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer pr...
The broadly neutralizing antibody 2G12 recognizes a conserved cluster of high-mannose glycans on the...
[[sponsorship]]基因體研究中心[[note]]已出版;[SCI];有審查制度;不具代表性[[note]]http://gateway.isiknowledge.com/gateway/G...
AbstractHuman antibody 2G12 broadly neutralizes human immunodeficiency virus type 1 (HIV-1) isolates...
Up to ∼20% of HIV-infected individuals eventually develop broadly neutralizing antibodies (bnAbs), a...
Some conserved glycans on the HIV envelope protein are targets of broadly neutralizing antibodies (b...
The glycan shield of human immunodeficiency virus type 1 (HIV-1) gp120 contributes to viral evasion ...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
The surface of enveloped viruses can be extensively glycosylated. Unlike the glycans coating pathoge...
The surface of enveloped viruses can be extensively glycosylated. Unlike the glycans coating pathoge...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
Lipooligosaccharides (LOS) from the bacterium Rhizobium radiobacter Rv3 are structurally related to ...
AbstractHuman antibody 2G12 broadly neutralizes human immunodeficiency virus type 1 (HIV-1) isolates...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer pr...
The broadly neutralizing antibody 2G12 recognizes a conserved cluster of high-mannose glycans on the...
[[sponsorship]]基因體研究中心[[note]]已出版;[SCI];有審查制度;不具代表性[[note]]http://gateway.isiknowledge.com/gateway/G...
AbstractHuman antibody 2G12 broadly neutralizes human immunodeficiency virus type 1 (HIV-1) isolates...
Up to ∼20% of HIV-infected individuals eventually develop broadly neutralizing antibodies (bnAbs), a...
Some conserved glycans on the HIV envelope protein are targets of broadly neutralizing antibodies (b...
The glycan shield of human immunodeficiency virus type 1 (HIV-1) gp120 contributes to viral evasion ...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
The surface of enveloped viruses can be extensively glycosylated. Unlike the glycans coating pathoge...
The surface of enveloped viruses can be extensively glycosylated. Unlike the glycans coating pathoge...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
Lipooligosaccharides (LOS) from the bacterium Rhizobium radiobacter Rv3 are structurally related to ...
AbstractHuman antibody 2G12 broadly neutralizes human immunodeficiency virus type 1 (HIV-1) isolates...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design....
To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer pr...